TL;DR Ozempic, the most searched of them, is registered in Hong Kong — but its US label is approved only for type 2 diabetes, with no weight-management indication. "Registered" and "approved for weight loss" are two different things. All five products' US labels carry the FDA's highest level of safety alert, a boxed warning. And a year after stopping, participants in the study had regained on average about two-thirds of the weight they had lost.
Are Ozempic, Wegovy and Saxenda registered in Hong Kong? All three are
The most-asked question first. The three brands readers search for most have each been verified by this site against the Hong Kong Pharmacy and Poisons Board's drug database as products registered in Hong Kong, searched on 2026-07-31.
| Brand | Active ingredient | Registration number |
|---|---|---|
| Ozempic | Semaglutide | HK-66485／66486／66487 |
| Wegovy | Semaglutide | HK-67962 to 67966 |
| Saxenda | Liraglutide | HK-65010／67971 |
All three are Novo Nordisk injection pen products.
"Registered" is not "approved for weight loss" — and Ozempic is the example
This is the most important sentence in the article: "registered" does not mean "that brand is approved for weight loss".
The reason is quite specific. The Hong Kong drug register does not publicly set out the approved indications for each product, and under the same active ingredient different brands can have different approved uses — some approved for diabetes.
Three things need keeping apart, not two:
| Idea | Example |
|---|---|
| Active ingredient | Semaglutide |
| Registered brand | Ozempic, Wegovy |
| Approved indication | Varies by product; governed by the product's registration and the doctor's prescription |
"Slimming injections" are not one interchangeable class of drug.
⚠️ If you have seen a brand name online and want to shop around, this step cannot be skipped: whether the brand you are talking about is approved for weight loss is something only a doctor, reading the product's registration particulars, can answer.
How a diabetes drug became the most sought-after injection in the world
GLP-1 receptor agonists began life as type 2 diabetes drugs.
Take the EU registration record. Liraglutide was approved in the EU under the brand Victoza on 30 June 2009 for type 2 diabetes; semaglutide was approved in the EU under the brand Ozempic on 8 February 2018, also for type 2 diabetes.
The same ingredients were only later approved, under separate brands, for weight management: Saxenda (liraglutide) on 23 March 2015 and Wegovy (semaglutide) on 6 January 2022.
That is EU registration history, given as background; it is not a statement of Hong Kong indications.
"Most sought-after in the world" is not an adjective here but a fact a regulator has put on the record. The European Medicines Agency's Medicine Shortages Steering Group states that these medicines have been in shortage across EU member states since 2022, the shortage being due to increased demand together with other causes such as manufacturing capacity constraints; the same document raises concern that some of these medicines are being used excessively off-label for cosmetic weight loss — that is, in people who are neither obese nor overweight with a weight-related health problem — and that this use, mentioned frequently in the news and on social media, is exacerbating existing shortages with serious consequences for public health [Note 1].
After shortage comes counterfeit. In October 2023 authorities in EU member states found falsified Ozempic in the supply chain, and the European Medicines Agency issued an alert to patients and healthcare professionals. (The Agency's shortages catalogue page was updated on 13 January 2026: the Ozempic shortage is resolved.)
⚠️ Anyone thinking "so many people use it, it must be fine" should think again: a market where demand outstrips supply is exactly the market where off-label use and counterfeits are busiest.
How does it take weight off? The original wording is "appears to"
Take Wegovy. The product overview approved by the European Medicines Agency describes how it works like this: the medicine acts in the same way as GLP-1, a natural hormone in the body, and among other things appears to regulate appetite by increasing a person's feelings of fullness while reducing their food intake, hunger and cravings [Note 2].
"Among other things" and "appears to" are the source's own words, not reservations this article has added.
The pharmacological detail of an individual product, dose escalation included, is governed by its registered prescribing information and by what the doctor explains.
How much did people lose? 14.9% over 68 weeks — but stopping needs a different set of figures
The main study and the extension study are two sets of figures with different purposes, and they cannot be run together.
The main study (STEP 1): 1,961 adults with obesity or overweight and without diabetes (BMI≥30, or BMI≥27 with one weight-related condition), randomised 2:1 to semaglutide injection (2.4 mg subcutaneously once weekly) or placebo, both groups also receiving a lifestyle intervention.
After 68 weeks the semaglutide group had lost on average 14.9% of body weight against 2.4% in the placebo group, an estimated treatment difference of 12.4 percentage points (95% confidence interval 11.5 to 13.4).
What happens after stopping has to be answered from a much smaller set of figures. The extension study followed only 327 of the participants who completed the 68 weeks of treatment — a representative subgroup, not all 1,961.
| Time point | Semaglutide subgroup | Placebo subgroup |
|---|---|---|
| Weeks 0 to 68 (treatment period) | Lost 17.3% of body weight | Lost 2.0% |
| Regain one year after stopping | Regained 11.6 percentage points | Regained 1.9 percentage points |
| Net loss at week 120 | 5.6% | 0.1% |
Put another way: a year after stopping, the semaglutide subgroup had regained about two-thirds of the weight lost during treatment. "Stopping" here means stopping the once-weekly injection together with the lifestyle intervention.
The direction of the conclusion is clear enough: the weight lost during treatment is real, and so is most of the rebound after stopping. Weight management is a long-term matter, not a matter of one injection.
⚠️ If money is tight and the plan is "a few months until it works, then stop", these two sets of figures belong in the conversation with the doctor before starting.
What class of drug is this in Hong Kong
Injectable medicines registered in Hong Kong for the treatment of obesity include liraglutide, semaglutide and tirzepatide — the official list says "include", and is not exhaustive.
These ingredients are all Part 1 poisons and prescription drugs under the Pharmacy and Poisons Ordinance (Cap. 138) — that is, Schedule 3 Poisons — and require a registered doctor's prescription [Note 6].
According to the Drug Office bulletin of December 2025, the preparations registered in Hong Kong containing GLP-1 receptor agonists and dual agonists include:
| Ingredient | Registered products |
|---|---|
| Semaglutide | 11 |
| Tirzepatide | 6 |
| Liraglutide | 5 |
| Dulaglutide | 4 |
All are prescription-only. Dispensing involves the statutory roles of pharmacists, authorised sellers of poisons and the supply chain. Unlicensed online purchase, buying agents, and beauty salons selling injections themselves are none of them lawful routes.
Five US labels, five identical boxed warnings
A "boxed warning" is the highest level of safety alert on a US Food and Drug Administration prescription drug label.
The five products sold in the US that this article covers — Wegovy, Ozempic, Saxenda, Zepbound, Mounjaro — were each checked in their 2026 versions through the official label database, and all five labels carry the same boxed warning: the risk of thyroid C-cell tumours [Note 3].
⚠️ The contraindications are consistent across all five: people with a personal or family history of medullary thyroid carcinoma, people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and people with a serious hypersensitivity reaction to the ingredients or excipients must not use them.
The differences between the five labels are mainly the drug name and a small amount of wording in the animal-study description [Note 4].
But a boxed warning read on its own is incomplete — the five products' US labels are approved for different uses.
| Product | Ingredient | Registered in Hong Kong | US label approved use |
|---|---|---|---|
| Wegovy | Semaglutide | Yes (HK-67962 to 67966) | Weight loss, cardiovascular risk, a category of liver disease |
| Ozempic | Semaglutide | Yes (HK-66485／66486／66487) | Type 2 diabetes only |
| Saxenda | Liraglutide | Yes (HK-65010／67971) | Weight loss |
| Zepbound | Tirzepatide | Not found on a 2026-07-31 search | Weight loss, obstructive sleep apnoea |
| Mounjaro | Tirzepatide | Yes (HK-68408 to 68413) | Type 2 diabetes only |
Each approved use in that table carries qualifying conditions, and those conditions are decisive: Wegovy's weight-loss indication applies to people aged 12 or over with obesity, or adults who are overweight with one weight-related condition; it is separately approved to reduce the risk of major cardiovascular events in adults with obesity or overweight who already have cardiovascular disease. Saxenda's weight-loss indication applies to people aged 12 or over weighing more than 60 kg with obesity, or adults who are overweight with one weight-related condition. Zepbound is for adults with obesity or adults who are overweight with one weight-related condition, and is separately approved for moderate-to-severe obstructive sleep apnoea in adults with obesity. Ozempic's type 2 diabetes indication covers glycaemic control, cardiovascular risk and progression of chronic kidney disease; Mounjaro's is glycaemic control.
Putting the two together: the tirzepatide product registered in Hong Kong (Mounjaro) is approved on its US label only for diabetes, and the tirzepatide product the US approved for weight loss (Zepbound) was not found on the Hong Kong register when this article searched.
And Ozempic, the one readers search for most, is in the same position: registered, but approved on its US label only for diabetes, not for weight loss.
⚠️ This table is not a complete list of risks. Each of the five labels also has around ten "warnings and precautions" sections, including but not limited to acute pancreatitis, acute gallbladder disease, acute kidney injury from fluid loss, severe gastrointestinal reactions, diabetic retinopathy complications, increased heart rate and hypersensitivity reactions, none of which this article lists individually. Whether you or your family have any of those histories, and whether this class of drug suits you, is for a doctor to assess — not something a reader can settle by ticking off this table.
That December 2025 bulletin was actually about suicidal ideation warnings
The product counts quoted above come from the Drug Office bulletin of December 2025, but that bulletin is not itself about product counts.
Its actual subject is Australia aligning the warning wording on the class of GLP-1 receptor agonists over a potential risk of suicidal thoughts or behaviours [Note 5].
The bulletin cites the Australian Therapeutic Goods Administration: its advisory committee on medicines considered the available evidence insufficient to establish a link between GLP-1 receptor agonists and suicidal or self-harming behaviour, while noting that the product information and prescribing guidance for drugs in the same class were inconsistently worded and should be aligned.
The bulletin closes by stating: in the light of the Australian announcement, the Registration Committee of the Pharmacy and Poisons Board of Hong Kong will discuss the matter.
The position in the US is different again. As at the search date, the Wegovy, Saxenda and Zepbound labels had marked this warning as "(Removed, February 2026)", and the current Ozempic and Mounjaro labels do not carry it at all.
So this signal is at a stage where regulators do not entirely agree, and is not a settled warning — but Hong Kong's own regulator has begun discussing it because of it, which is worth knowing.
Common side effects, and medical supervision
The Wegovy product information approved by the European Medicines Agency lists the most common side effects (which may affect more than one in ten users) as headache, nausea, vomiting, diarrhoea, constipation and abdominal pain.
The Department of Health's announcement of 2026-03-04 separately lists the side effects of tirzepatide as hair loss, nausea and diarrhoea.
As for why medical supervision is required, the official wording is direct: these medicines "should only be used under close supervision of doctors", and members of the public should "strictly adhere to the treatment plans prescribed by doctors" [Note 6]. A doctor assesses whether the medicine is suitable and follows up the response.
Online, buying agents, beauty salons: 41 convictions and two sentencing figures
On 4 March 2026 the Department of Health acted against the illegal online sale of a controlled anti-obesity medicine (tirzepatide), warning that "the safety, quality and efficacy of unregistered pharmaceutical products are not guaranteed" [Note 7].
Medicines from illegal sources may not have been properly stored in transit, which affects their safety.
Enforcement is not abstract. In the year from 2025-04-01 to 2026-03-31 there were 41 convictions involving the illegal sale or possession of unregistered pharmaceutical products or Part 1 poisons, weight-loss injections among them.
The statutory maximum penalty for this kind of conviction is a fine of $100,000 and two years' imprisonment. Among those 41 cases, the heaviest sentences imposed were two months' imprisonment (suspended for three years), or a fine of $87,000 — two figures that mark what has actually happened, not what every case attracts.
Penalties have to be read against the actual charge and the statutory provisions, and should not be generalised into "possessing GLP-1 medicines is illegal": a patient lawfully holding a registered medicine on prescription is not the same thing at all.
⚠️ If you have seen a beauty salon or buying agent advertising a big discount: behind that price gap is an unregulated source, and those 41 convictions are an official figure.
How many people in Hong Kong are overweight?
Department of Health Population Health Survey 2020-22: among people aged 15–84, 32.6% were obese (BMI≥25) and a further 22.0% were overweight, about 54.6% in total.
That is the background to demand for weight-loss medicines. But whether a medicine suits an individual can only be decided by a doctor after assessment.
What to do next
- First find out what the brand you want is actually approved for in Hong Kong. Registered is not approved for weight loss, and the register does not publicly set out indications, so this step means asking a doctor.
- Give your full history, particularly any family history of medullary thyroid carcinoma and MEN 2. Those are the contraindications all five labels share.
- Talk about stopping before you start. In the study, a year after stopping about two-thirds of the weight lost had been regained, so plan on a long-term basis.
- Do not buy injections online, through a buying agent or from a beauty salon. Source, storage and authenticity are all unguaranteed, and enforcement is real.
- The basics outside medicine do not change: diet and physical activity. The World Health Organization recommends 150–300 minutes of moderate-intensity aerobic activity a week for adults.
- If you have doubts about a product of unknown provenance, you can ask or report it to the Department of Health's Drug Office.
- This site holds no prescription drug price data and recommends no brand or source of supply. For the level of consultation fees, see Private doctors' fees explained.
Frequently asked questions
Is Ozempic a weight-loss injection in Hong Kong?
Ozempic is registered in Hong Kong (HK-66485／66486／66487), but its US label is approved only for type 2 diabetes, with no weight-loss indication. The Hong Kong drug register does not publicly set out the approved indications for each product, so what a particular Hong Kong-registered brand is actually approved for is a question for a doctor.
What are the "slimming injections" in Hong Kong?
The official reply states that injectable medicines registered for the treatment of obesity include liraglutide, semaglutide and tirzepatide — "include", not an exhaustive list. All are Part 1 poisons and prescription drugs, and require a registered doctor's prescription.
Does the same ingredient mean it is approved for weight loss?
No. Three things need keeping apart: the active ingredient, the registered brand, and the approved indication. Under the same ingredient not every registered brand is approved for weight management; some are approved for diabetes. It is governed by the product's registration and the doctor's prescription.
How much weight comes off, and does it come back after stopping?
In the main study of 1,961 adults with obesity or overweight and without diabetes, the semaglutide group had lost on average 14.9% of body weight after 68 weeks against 2.4% on placebo. The extension study followed only 327 of those who completed treatment: a year after stopping both the injection and the lifestyle intervention, the semaglutide subgroup had regained about two-thirds of the weight lost, with a net loss of 5.6% at week 120. The study's authors state themselves that this extension analysis is exploratory.
Do these medicines carry a highest-level safety alert?
Yes. The US labels of all five products sold in the US — Wegovy, Ozempic, Saxenda, Zepbound and Mounjaro — carry an FDA boxed warning on the risk of thyroid C-cell tumours. People with a personal or family history of medullary thyroid carcinoma, people with MEN 2, and people with a serious hypersensitivity reaction to the ingredients or excipients must not use them. Each of the five labels also has around ten "warnings and precautions" sections, which this article does not list individually.
I have heard these drugs are linked to suicidal thoughts — is that true?
It is at a stage where regulators do not entirely agree. The Australian Therapeutic Goods Administration's advisory committee on medicines considered the available evidence insufficient to establish a link between GLP-1 receptor agonists and suicidal or self-harming behaviour, but took the view that wording across the class should be aligned; the Registration Committee of the Pharmacy and Poisons Board of Hong Kong will discuss the matter as a result. In the US, the Wegovy, Saxenda and Zepbound labels have marked this item as "(Removed, February 2026)", and the current Ozempic and Mounjaro labels do not carry it at all.
Can I buy slimming injections online or from a beauty salon?
No. Unlicensed online purchase, buying agents and beauty salons selling injections themselves are none of them lawful routes. The Department of Health warns that the safety, quality and efficacy of unregistered pharmaceutical products are not guaranteed, and medicines from illegal sources may not have been properly stored in transit. In the year from 2025-04-01 to 2026-03-31 there were 41 relevant convictions.
What does a slimming injection cost?
This site holds no prescription drug price data and will not recommend any brand or source of supply. For the level of consultation fees, see [this platform's article on private doctors' fees](/articles/private-doctor-fees).
If I would rather not take a medicine, what are the basics?
The basis of weight management remains diet and physical activity. The World Health Organization recommends 150–300 minutes of moderate-intensity aerobic activity a week for adults. Whether a medicine is suitable is for a doctor to assess.
What this article does not state
- This article gives no advice on taking medicines and recommends no brand or source of supply.
- The approved indications of individual products registered in Hong Kong. The Hong Kong drug register does not publicly set them out, so this article cannot state them; every "approved use" in this article is US label content, not a statement of Hong Kong registered indications.
- Drug prices. This site holds no prescription drug price data.
- A complete list of risks. Each of the five labels has around ten warnings and precautions sections, which this article does not list one by one.
- Dose escalation for individual products. Governed by the registered prescribing information and by what the doctor explains.
- The specific storage requirements of medicines from illegal sources. Governed by each product's registered prescribing information and the pharmacist's instructions; this article does not generalise.
- Penalties cannot be generalised. They have to be read against the actual charge and the statutory provisions, and should not be read as "possessing GLP-1 medicines is illegal" — a patient lawfully holding a registered medicine on prescription is not the same situation.
- EU registration history is background only. The EU approval dates and indications in this article do not constitute a statement of Hong Kong indications.
- The standing of the extension study. The authors state themselves that the extension analysis is exploratory, and its 327-participant subgroup figures cannot be used to represent the 1,961-participant main study.
- The English-language sources have no Chinese edition. The European Medicines Agency's Wegovy product overview exists in 23 language versions, none of them Chinese; the Agency's shortage document and that Drug Office bulletin have no Chinese version either (the bulletin's /EN/, /ZH/ and /TC/ language paths were each checked and all three serve the same English PDF). The passages quoted in this English edition are the sources' own English.
Notes: the official wording
The passages below are quoted verbatim from the sources' own English.
[Note 1] European Medicines Agency Medicine Shortages Steering Group recommendation document EMA/143883/2024 (12 June 2024):
"The shortage is due to an increased demand for these medicines in conjunction with other causes, such as manufacturing capacity constraints." … "Excessive off-label use for cosmetic weight loss of some of these medicines has raised concerns." … "This use has been mentioned frequently in the news and social media and is exacerbating existing shortages with serious consequences for public health."
[Note 2] The European Medicines Agency Wegovy product overview (EMA/162766/2023), on how it works. That overview exists in 23 language versions, none of them Chinese:
"It acts in the same way as GLP-1 (a natural hormone in the body) and, among other things, appears to regulate appetite by increasing a person's feelings of fullness, while reducing their food intake, hunger and cravings."
[Note 3] The full boxed warning from Wegovy's US approved prescribing information (2026-06-18 version). This is the US label, not Hong Kong registration particulars:
"WARNING: RISK OF THYROID C-CELL TUMORS In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined. WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of WEGOVY and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with WEGOVY."
In plain terms: in rodents semaglutide causes thyroid C-cell tumours, the risk rising with dose and with how long the drug is taken; whether that carries over to humans, medullary thyroid carcinoma included, is undetermined; and anyone with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2, must not use Wegovy.
[Note 4] The Ozempic, Saxenda, Zepbound and Mounjaro labels all carry a substantively identical boxed warning — the same core alert, the same set of contraindications — differing mainly in the drug name and a little of the animal-study wording: Wegovy and Ozempic write "in rodents", Saxenda writes "in both genders of rats and mice", Zepbound writes "in rats", and Mounjaro writes "in both male and female rats".
[Note 5] The title of the Drug Office bulletin of 1 December 2025:
"Australia: GLP-1 RAs: warnings aligned over potential risk of suicidal thoughts or behaviours"
The class the bulletin concerns is the GLP-1 receptor agonists. That bulletin has no Chinese version; its /EN/, /ZH/ and /TC/ language paths were each checked and all three serve the same English PDF.
[Note 6] The Secretary for Health's written reply in the Legislative Council of 13 May 2026, given after consulting the Department of Health, the Customs and Excise Department and the Police. The reply states that the injectable medicines registered for the treatment of obesity "are all Part 1 poisons and prescription drugs (i.e. Schedule 3 Poisons) under the Pharmacy and Poisons Ordinance (Cap. 138)". The Chinese edition of this article quotes only the part of that sentence bearing directly on classification; this English edition quotes it in full. The same reply states that in Hong Kong almost all anti-obesity medicines are prescription drugs and "should only be used under close supervision of doctors", and that members of the public should "strictly adhere to the treatment plans prescribed by doctors".
[Note 7] The Department of Health's warning wording on the illegal sale of controlled anti-obesity medicine:
"The safety, quality and efficacy of unregistered pharmaceutical products are not guaranteed."
Sources and dates checked
- Legislative Council written reply (ingredients, classification, the medical supervision wording, 41 convictions, sentencing figures): https://www.info.gov.hk/gia/general/202605/13/P2026051300203.htm, 2026-05-13.
- Department of Health crackdown on illegal online sale (tirzepatide; the unregistered-product warning; tirzepatide side effects): https://www.info.gov.hk/gia/general/202603/04/P2026030400657.htm, 2026-03-04.
- Drug Office bulletin (registered product counts by ingredient; its actual subject, Australia aligning suicidal-ideation warnings; the Hong Kong Registration Committee to discuss): https://www.drugoffice.gov.hk/eps/upload/eps_news/56493/EN/1/News%20Bulletin%201%20Dec%202025%20(GLP-1).pdf, 2025-12-01. Retrieved: 2026-07-31.
- Brand registration search (Ozempic／Wegovy／Saxenda／Mounjaro registration numbers; Zepbound not found): Hong Kong Pharmacy and Poisons Board drug database https://www.drugoffice.gov.hk/eps/do/en/consumer/search_drug_database.html. Retrieved: 2026-07-31.
- Wegovy mechanism and common side effects: European Medicines Agency product overview https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy. Retrieved: 2026-07-31.
- GLP-1 EU registration history: Victoza (2009-06-30, type 2 diabetes) https://www.ema.europa.eu/en/medicines/human/EPAR/victoza, Ozempic (2018-02-08, type 2 diabetes) https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic, Saxenda (2015-03-23, weight management) https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda; Wegovy (2022-01-06, weight management) see the entry above. Retrieved: 2026-07-31.
- GLP-1 shortages and off-label weight-loss use (increased demand, social media, falsified Ozempic): EMA MSSG recommendation document EMA/143883/2024 (2024-06-12) https://www.ema.europa.eu/system/files/documents/other/recommendations-mssg-shortage-glp-1-receptor-agonists_en.pdf; Ozempic shortages catalogue page (updated 2026-01-13: resolved) https://www.ema.europa.eu/en/medicines/human/shortages/ozempic. Retrieved: 2026-07-31.
- Main study STEP 1 (1,961 participants, 68 weeks, 14.9% against 2.4%, treatment difference 12.4 percentage points): Wilding JPH, et al.; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384(11):989–1002. DOI 10.1056/NEJMoa2032183; PMID 33567185. Retrieved: 2026-08-10.
- Weight regain after stopping (327-participant subgroup, 17.3%／2.0%, 11.6／1.9 percentage points, 5.6%／0.1% at week 120): STEP 1 extension study, Wilding et al., Diabetes Obes Metab 2022; PMID 35441470. Retrieved: 2026-07-31. Everything else retrieved 2026-07-27.
- US drug labels (boxed warnings, approved uses; official SPL database, with each setid and effective date verified): WEGOVY setid
ee06186f-2aa3-4990-a760-757579d8f77b(2026-06-18); OZEMPIC setidadec4fd2-6858-4c99-91d4-531f5f2a2d79(2026-06-01); SAXENDA setid3946d389-0926-4f77-a708-0acb8153b143(2026-02-25); ZEPBOUND setid487cd7e7-434c-4925-99fa-aa80b1cc776b(2026-04-22); MOUNJARO setidd2d7da5d-ad07-4228-955f-cf7e355c8cc0(2026-04-22). https://dailymed.nlm.nih.gov/dailymed/. Retrieved: 2026-08-10. These are US approved prescribing particulars, not Hong Kong registered indications. - Overweight and obesity rates (Population Health Survey 2020-22): https://www.chp.gov.hk/en/healthtopics/content/25/8802.html.
- Physical activity recommendation (WHO recommendation, Centre for Health Protection page): https://www.chp.gov.hk/en/healthtopics/content/100200/8804.html. Retrieved: 2026-07-30.
This article was written from the sources listed above. It is about regulatory facts, evidence and safety risk; whether this class of medicine suits you, and which product, it does not answer — that is for a registered doctor to decide on your history and your situation.
Further reading
- On this platform: Private doctors' fees explained
- Department of Health Drug Office: drugoffice.gov.hk